On October 10, 2019 Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, reported that it will present the first clinical data from its Phase 2 development program with novel, tumor-selective anti-EGFR ADC AVID100 at the 10th Annual World ADC in San Diego (Oct. 8 – 11) (Press release, Forbius, OCT 10, 2019, View Source [SID1234540933]). AVID100 clinical data will also be featured in an upcoming poster presentation at the AACR (Free AACR Whitepaper)-NCI-EORTC meeting in Boston (Oct. 26 – 30).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentations will present safety, pharmacokinetics and preliminary anti-tumor effect of AVID100 in previously treated HNSCC, NSCLC and TNBC patients with documented EGFR-overexpression (NCT03094169). Data from the parallel development of an EGFR companion diagnostic test used to select for EGFR-overexpressing tumors will also be presented.
Details of the Presentations Are as Follows:
World ADC
Oral presentation by Forbius’ Chief Scientific Officer, Dr. Maureen O’Connor
Title: Development of AVID100, an Anti-EGFR ADC with a Novel Mechanism for Tumor Selective Cytotoxicity
Date: Thursday, Oct. 10
Time: 11:30 AM PT
Clinical Stream
AACR-NCI-EORTC
Poster presentation by Forbius’ Chief Development Officer, Dr. Robert Lutz
Title: Novel anti-EGFR antibody-drug conjugate AVID100: A phase 2a trial in patients with EGFR-overexpressing advanced solid tumors
Date: Sunday, Oct. 27
Time: 12:30 – 4:00 PM ET
Location: Hall D, Hynes Convention Center
Clinical Trials Session
Abstract #A088
Link to online Program here (search for AVID100 to see abstract)